Radioimmunotherapy is an approach that conjugates a radiocative molecule to a specific anti-cancer antibody. For lymphomas is is most commonlu anti-CD20. Because lymphomas are highly sensitive to radiation, radioimmunotherapy (RIT) has been used with great success in consolidation therapy and, as a result, there is great interest in exploring the use of RIT, either as a single agent or as augmentation of HDC, as part of a conditioning regimen for ASCT. Yttrium is one type of radiactive conjugate that is being studies. Both the use of Yttrium labeled radioimmunotherapy for lymphoma and the use of Yttrium, usually used and approved for liver metastses is novel and expermental. Several studies that used different RIT approaches suggested a gain in efficacy by using radioimmunotherapy but it requires more study.
Christian Gisselbrecht et al, Radioimmunotherapy for Stem Cell Transplantation in Non-Hodgkin’s Lymphoma: In Pursuit of a Complete Response
The Oncologist October 2009 vol. 14 Supplement 2 41-51
W A Bethge, Dose-escalated radioimmunotherapy as part of reduced intensity conditioning for allogeneic transplantation in patients with advanced high-grade non-Hodgkin lymphom
Bone Marrow Transplantation , (16 April 2012)